Although preclinical data suggest antitumor activity of FGFR inhibitors in FGFR2‐amplified cancers, clinical trials evaluating efficacy and safety failed to demonstrate clinical benefits of FGFR inhibitors in FGFR2‐amplified cancers. Here, FGFR2 is linked to cancer.